Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma
- 31 July 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (15), 3632-3643
- https://doi.org/10.1158/1078-0432.ccr-18-0041
Abstract
Purpose: Immune checkpoint inhibitors designed to revert tumor-induced immune suppression have emerged as potent anti-cancer therapies. Tryptophan metabolism represents an immune checkpoint and targeting this pathway's rate limiting enzyme IDO1 is actively being investigated clinically. Here, we studied the intermediary metabolism of tryptophan metabolism in glioblastoma and evaluated the activity of the IDO1 inhibitor GDC-0919, both alone and in combination with radiation (RT). Experimental Design: LC/GC-MS and expression profiling was performed for metabolomic and genomic analyses of patient-derived glioma. Immune competent mice were injected orthotopically with genetically engineered murine glioma cells and treated with GDC-0919 alone or combined with RT. Flow-cytometry was performed on isolated tumors to determine immune consequences of individual treatments. Results: Integrated cross-platform analyses coupling global metabolomic and gene-expression profiling identified aberrant tryptophan metabolism as a metabolic node specific to the mesenchymal and classical subtypes of glioblastoma. GDC-0919 demonstrated potent inhibition of this node and effectively crossed the blood brain barrier. Although GDC-0919 as a single agent did not demonstrate anti-tumor activity, it had a strong potential for enhancing RT response in glioblastoma, which was further augmented with a hypofractionated regimen. RT response in glioblastoma involves immune stimulation, reflected by increases in activated and cytotoxic T-cells, which was balanced by immune checkpoint reactivation, reflected by an increase in IDO1 expression and Tregs. GDC-0919 mitigated RT-induced Tregs and enhanced T-cell activation. Conclusion: Tryptophan metabolism represents a metabolic node in glioblastoma and combining RT with IDO1 inhibition enhances therapeutic response by mitigating RT-induced immune suppression.Keywords
Other Versions
Funding Information
- NIH NCI (R01CA204136)
This publication has 53 references indexed in Scilit:
- Evolutionary etiology of high-grade astrocytomasProceedings of the National Academy of Sciences of the United States of America, 2013
- Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3Proceedings of the National Academy of Sciences of the United States of America, 2013
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanismProceedings of the National Academy of Sciences of the United States of America, 2010
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T CellsThe Journal of Immunology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Inflammatory Signaling and Aryl Hydrocarbon Receptor Mediate Synergistic Induction of Interleukin 6 in MCF-7 CellsCancer Research, 2008
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptorNature, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006
- Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T LymphocytesCancer Research, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004